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Exposure of fibrinogen and thrombin to nitric oxide donor ProliNONOate affects fibrin
clot properties.
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Abstract
Background
Fibrin fibers form the structural backbone of blood clots. The structural properties of fibrin clots
are highly dependent on formation kinetics. Environmental factors such as protein concentration,
pH, salt and protein modification, to name a few, can affect fiber kinetics through altered
fibrinopeptide release, monomer association and/or lateral aggregation.

Objective
To determine the effect of thrombin and fibrinogen exposed to nitric oxide on fibrin clot properties.

Methods
ProliNONOate (5 µM) was added to fibrinogen and thrombin before clot initiation and immediately
following the addition of thrombin to the fibrinogen solution. Resulting fibrin fibers were probed with
an atomic force microscope to determine their diameter and extensibility and fibrin clots were
analyzed for clot density using confocal microscopy. Fiber diameters were also determined by
confocal microscopy and the rate of clot formation was recorded using UV-vis spectrophotometry.
Protein oxidation and S-nitrosation was determined by UV-vis, ELISA and chemiluminescence.

Results
The addition of ProliNONOate to fibrinogen or thrombin resulted a change in clot structure.
ProliNONOate exposure produced clots with lower fiber density, thicker fibers and increased time
to maximum turbidity. The effect of the exposure of nitric oxide to thrombin and fibrinogen were
measured independently and indicated that each plays a role in altering clot properties.
detected thrombin S-nitrosation and protein carbonyl formation after nitric oxide exposure.

Conclusions

We
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Our study reveals a regulation of fibrin clot properties by nitric oxide exposure and suggests a
role of peroxynitrite in oxidative modifications of the proteins.

These results relate NO

bioavailability and oxidative stress to altered clot properties.

Keywords:
Fibrinogen, Post-translational modification, Nitric Oxide, Thrombin, Blood Coagulation
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Introduction:
Fibrin fibers are a major component in the structure of blood clots. They provide support to blood
clots through the formation of a branching network of fibers. Fibrin fibers are formed from
soluble fibrinogen after removal of fibrinopeptides A and B by the serine protease thrombin.
Removal of fibrinopeptides A and B expose charged knobs which interact with oppositely
charged holes on the distal region of a different fibrin monomer. This charge-charge interaction
leads to protofibril formation and is followed by lateral association resulting in fiber formation
and ultimately a branched fiber network. Additional covalent bonds are formed between fibrin
molecules by transglutaminase, FXIIIa, after polymerization.

Fibrin network properties, both structural and mechanical, are influenced by polymerization
conditions including thrombin concentration, fibrinogen concentration, methionine oxidation, pH,
ionic strength, calcium concentration, and tyrosine nitration [1-9]. Structural changes at the
single fiber and whole clot level affect the mechanical properties of fibrin clots. Li et al showed
smaller fibrin fibers have a higher individual moduli than larger fibers and Ryan et al showed
fibrin clot modulus varies with fiber density, fiber diameter, fiber length, and branch point density
[9-11]. Structural and mechanical variations to the fibrin network alter the rate of clot fibrinolysis
[12,13] and alter cell infiltration and cellular biochemical function [14]. Altered network properties
have been linked to clotting disorders and diseases such as hemorrhaging, thrombosis,
myocardial infarction, and stroke [11,15]. For example, myocardial infarction can be linked to an
increased storage modulus, G’ [9,15,16]. Altered clot architecture has been linked to diabetes,
chronic heart failure and abdominal aortic aneurysms [17,18,18].

In this manuscript, we investigate the effect of nitric oxide (NO) exposure on fibrin clot
properties. Supraphysiological levels of nitric oxide are known to effect the activity of factor XIIIa
[19] and therefore the crosslinking for fibrin fibers. Here we focus on the exposure of thrombin

5
and fibrinogen to NO through NO donor, ProliNONOate. This study is motivated by the results of
Davis et al. who reported a decrease in detection of NO produced by endothelial cells in the
presence of fibrin and suggested this decrease in NO was due to a fibrin NO interaction [20].

The bioavailability and role of NO in cardiovascular signaling is a highly studied subject [21,22].
Although NO was originally thought to be short lived in the blood stream recent research
suggests NO remains active in the blood stream through various mechanisms [23-26]. For
example, the effect of NO metabolite, nitrite, on blood flow suggests the reduction of nitrite to
NO in the blood stream [27]. In addition to the direct interaction between NO and fibrin clots
suggested by Davis et al. byproducts of NO can interact with proteins and lead to modifications
such as nitration, carbonyl formation and/or S-nitrosation.

Previous work looking at protein modifications has shown that fibrin tyrosine nitration increased
clotting rate at low concentrations and decreased clotting rate at high concentrations [28]; while
thrombin tyrosine nitration decreased thrombin activity [29]. The physiological relevance of
these modifications is supported by measurements of S-nitrosation of plasma proteins such as
albumin at physiological NO concentrations as well as shown implications of hypo or hyper Snitrosation of blood proteins in disease states [22,30]. Similarly, studies reported protein
nitration in many diseases such as cardiovascular diseases, Alzheimer’s disease and
Parkinson’s disease [31-33]. Specifically nitrated fibrinogen is a risk factor in venous
thromboembolism [34].

In this article, we investigated the role of in vitro nitric oxide exposure on fibrin clot properties
and measured protein S-nitration, tyrosine nitration and carbonyl formation. We determined NO
exposure via ProliNONOate lead to these modifications.
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Methods
All experiments were performed in fibrin buffer (pH 7.4, 10 mM HEPES, 5 mM CaCl2, 140 mM
NaCl). Clots were formed from 1 mg/ml fibrinogen (Louisville APL Diagnostics, Doraville, GA,
USA) mixed with fibrin buffer and 55 Lowey U/ml FXIIIa, where indicated, (Enzyme Research
Laboratory, IN, USA) and clotting was initiated with the addition of thrombin (Enzyme Research
Laboratory, USA).

Nitric oxide donor, ProliNONOate (Cayman Chemical, MI, USA) is stable in alkaline solutions
but dissociates in a pH dependent manner. Its half-life is 1.8 seconds at 37 C
֯ in pH 7.4.
Therefore, ProliNONOate was suspended in 0.01 NaOH at a stock concentration of 75 µM and
was added in small volumes to the indicated protein solutions with a final concentration of 5 µM.
ProliNONOate concentration was determined by absorbance at 252 nm. The addition of
ProliNONOate to the protein samples raised the pH of the samples from 7.4 to 7.5 and therefore
controls were run with an equal volume of NaOH added to the sample to rule out any pH effect.

To determine the effect of ProliNONOate on fibrin clot properties, 5 µM ProliNONOate was
added to fibrinogen prior to clot formation (Fibrinogen + NO), 5 µM ProliNONOate was added to
thrombin prior to clot formation (Thrombin + NO) or 5 µM ProliNONOate was added to the clot
solution immediately following the addition of thrombin and the solution was briefly mixed (All +
NO). Care was taken to perform this step quickly to avoid polymerization during mixing.

Fiber density by confocal microscopy
Two # 1.5 cover slides were coated with Sigmacote (Sigma-Aldrich, St. Louis, MO, USA) prior to
clot formation. Fibrin clots were prepared from 1 mg/ml fibrinogen, comprised of 10% Alexa
488-labelled fibrinogen (Invitrogen, Grand Island, NY, USA) and 90% unlabeled fibrinogen in
fibrin buffer. Clot formation was initiated by the addition of 1 NIH unit/ml thrombin to the
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fibrinogen solution. ProliNONOate was added as indicated above. Immediately following the
addition of thrombin, the fibrin clot solution was placed on a coated cover slip inside a sealed
humidity chamber. The clot was left to polymerize in the humidity chamber for 2 hours at room
temperature. Coverslips were then sealed in holders to minimize drying of samples during
imaging. Confocal images were obtained within 24 hours of clot initiation to ensure minimal
buffer evaporation using a Leica SP2 inverted confocal microscope with a 63X, 1.43 NA oil
immersion lens using a 488 nm Argon laser. Regions of the clot were randomly selected and 30
slices of resolution 1024 x 1024 pixels were taken at an interval of 0.25 µm in z. Images were
obtained from three regions of each clot. A minimum of 12 clots were analyzed for each sample
condition.

Image J software (NIH) was used to analyze the images. Fibrin fiber density of each images
stack were determined as previously described by Hugenholtz et al [35]. Briefly, lines were
placed across the slices at 10 µm increments and averaging number of fibers intersecting the
line were recorded. Fiber densities of three different regions per sample were averaged.

Fibrin Fiber Diameter by AFM
Fibrin fibers were formed on top of freshly cleaved mica by adding 0.5 NIH u/ml thrombin to 1
mg/ml fibrinogen and ProliNONOate as indicated. The fibers polymerized in a humidity
controlled environment for 2 hours before they were rinsed and air dried. The diameters of the
dried fibrin fibers were determined by AFM using AC or intermittent contact mode (Asylum MFP3D Bio AFM and MikroMash CSC37). AFM scans were taken for a scan range of 5 µm x 5 µm
at a scan rate of 1 Hz and profile plots of line segments were used to determine fiber diameter.
Tip contact with the fibers during scanning can compress the fibrin fibers therefore reducing
fiber heights. Similarly, the conical shape of the tip causes tip broadening effects increasing the
width of the fibers. Therefore, we followed the procedure used by Domingues et al. and
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measured the width of the fiber at half the maximum height to reduce error due to compression
and tip broadening [36] (see Figure 2).

A minimum of 69 fibers were imaged for each sample

condition.

Fibrin Fiber Diameter by SEM
In addition to AFM diameter measurement, we determined fibrin fiber diameters by scanning
electron micrographs. Clots were formed on Sigma Cote treated glass slides with 0.5 U/ml
thrombin, 1mg/ml Fibrinogen, 55 units of Factor XIII and 5 μM ProliNONOate or NaOH as
indicated. Samples formed in a humid chamber for a minimum of 2 hours before they were
rinsed with HEPES buffer and fixed with a 2% gluteraldehyde solution for 30 minutes. The clots
were rinsed and stained with a 1% osmium tetroxide solution for 15 minutes and rinsed again.
Clots sat in dilutions of 50%, 80%, and 95% ethanol for 30 minutes each before being critical
point dried on the Tousimis Samdri-795 Critical Point Dryer. The samples were sputter coated,
mounted and imaged on the Jeol SEM at 10kV.

Turbidity by UV-vis spectroscopy
Clots were formed with 0.16 u/ml thrombin and 5 μM ProliNONOate, as indicated, in disposable
micro UV-Cuvettes (BrandTech Scientific, Essex, CT). Using a 10S Genesys UV-Vis
Spectrophotometer (Thermo Scientific, MA, USA), absorbance was measured at 350 nm every
10 seconds for 1-2 hours. The measurements began immediately following the addition of
thrombin. We calculated the initial rate of fiber polymerization (OD/s during the first minute after
the lag period), the clotting rate (OD/s at ½ max OD), and the clotting time (time at maximum
slope) (n ≥ 5). The first optical density measurement was used to baseline the data and the lag
period was defined as the time before the OD increased beyond 0.05.

Extensibility by AFM
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The ridged substrate was formed from Norland optical adhesive 81 (Norland Products, NJ,
USA) using soft lithography and a PDMS stamp as previously described [37,38]. Fibrin fibers
were formed on top of the 12 micron wide ridges by adding 0.5 NIH u/ml thrombin and 5 µM
ProliNONOate as indicated. The sample polymerized for 2 hours and then was rinsed with
fibrinogen buffer to remove excess fibers. 24 nm carboxylated fluorescent beads (Life
Technologies, Grand Island NY, USA) were diluted in calcium free fibrinogen buffer and were
nonspecifically added to the sample. Fibers were visualized using an inverted fluorescence
microscope (Zeiss, Thornwood NY, USA). Fibers were manipulated using an MFP-3D Bio AFM
(Asylum Research, Santa Barbara CA, USA) and controlled step script allowing cantilever
manipulation in the x, y, and z directions. Only fibers that were aligned perpendicular to or
approximately perpendicular to the ridges were manipulated. An AFM cantilever was used to
pull the fibrin fiber perpendicular to its orientation until it broke. To ensure that fibers were
extended to their breaking points, samples that detached from the ridges were excluded. The
process was recorded using a CCD camera and Zen software (AxioCam MRm, Zeiss, USA).
The initial and final lengths of the fibers were measured from the video images. The strain was
calculated for each sample by dividing the change in length by the initial length. The
extensibility of at least 18 fibers were determined for each fiber formation condition.

Protein S-nitrosation by ozone chemiluminescence
5 µM ProliNONOate was added to 1 µM protein. Protein S-nitrosation was measured by
reductive chemiluminescence using the Nitric Oxide Analyzer (NOA), (GE Analytical
Instruments, Boulder, CO). Aliquots of sample were injected into the copper-cysteine assay,
described previously [39], in the purge vessel of the NOA to measure the NO released. The
sample was treated with or without 5mM mercury chloride to ensure the signal was from a S-NO
bond.
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Tyrosine Nitration by ELISA
Nitrotyrosine concentrations were measured using a commercially available nitrotyrosine
competitive ELISA (Cell Biolabs Inc, San Diego, CA). 1 mg/ml fibrinogen and 2 NIH u/ml
thrombin were exposed to 5 µM ProliNONOate and were tested using the ELISA to quantify
nitrotyrosine formation. The ELISA was completed as indicated by the instructions. Briefly, the
samples and anti-nitrotyrosine antibody were added to the wells of a 96 well plate coated with
nitrated BSA. After an incubation period the wells were rinsed and a horseradish peroxidase
secondary antibody was added for colorimetric detection. Absorbance measurements from the
wells with the samples were compared to a nitrated BSA standard curve.

Carbonyl detection
Protein carbonyl concentration was determined by UV-vis spectrophotometry using a simplified
alkaline 2,4-dinitrophenylhydrazine (DNPH, TCI America) assay. Samples with 3 mg/ml
fibrinogen or 20 µM Thrombin and 5 µM ProliNONOate or equal volume NaOH were prepared
and mixed in equal parts with 10 mM DNPH. DNPH reacted with ketones or aldehydes to form
a derivative with an absorbance peak around 370 nm, similar to the absorbance of free DNPH.
The maximum wavelength of the hydrazine derivative was shifted by the addition of 1.2 M
NaOH and subsequent 10 minute incubation, as described by Mesquita et al [40]. Carbonyl
concentrations were determined using a molar extinction coefficient of 22,308 M-1 cm-1 [40].

Statistics
Data is reported as the mean ± standard deviation unless indicated otherwise. Statistical

significance was determined by performing a two-tailed, homoscedastic student t-test and pvalues are reported.

Results
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We suspended ProliNONOate in NaOH for stability and prepared it at a high stock concentration
to limit the amount of NaOH added to the samples during the addition of ProliNONOate. We
added NaOH to the samples at a ratio of 1 part NaOH to 14 parts sample. The addition of NaOH
to fibrin buffer at a ratio of 1:14 raised the pH from 7.4 to 7.5. Therefore, we added NaOH to
control samples at a volume equal to that of ProliNONOate addition to account for any effect of
pH control.

Additionally, due to assay limitations the thrombin concentration changed between assays. We
indicated thrombin concentration for each assay in the methods section. Therefore, one must
take care when interpreting the results taken at various concentrations.

Clot density
Using confocal microscopy, we first tested for changes in clot density due to the addition of
ProliNONOate. The addition of 5 µM ProliNONOate immediately following the addition of
thrombin to the fibrin clot solution (All + NO) decreased the fiber density of the clot compared to
controls (Figure 1). We noticed a by visual comparison a decrease in fiber density of the
sample image compared to the control image and confirmed the decrease quantitatively by
determining the average number of fibers intersecting lines drawn across the image. On
average, there were 10 ± 2 fibers (average ± standard deviation) intersecting a 238 µm line

passing through the NO + all sample while the control clot averaged 14 ± 5 fibers. The

decreased fiber density was significant (p < 0.05).

To determine if the effect was due to an interaction of ProliNONOate with thrombin or fibrinogen
we tested ProliNONOate exposure to thrombin and fibrinogen independently. The addition of 5
µM of ProliNONOate to thrombin, thrombin + NO, or fibrinogen, fibrinogen + NO, prior to clot
formation significantly reduced the numbers of fibers intersecting a line to 9 ± 2 and 10 ± 5,
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respectively (p < 0.01 and p < 0.05). We measured a more significant effect of ProliNONOate
addition to thrombin than to fibrinogen. Therefore, ProliNONOate had an effect on clot density
through its interaction with both fibrinogen and thrombin.

Fiber Diameter
A decrease in clot fiber density, may indicate an increase in fiber thickness. Therefore, we
tested fibrin fiber diameter in clots in the presences and absence of ProliNONOate. Using AFM,
we measured the full width of the fibers at half their maximum height to minimize compression
and tip broadening effects. Additionally, we measured fiber diameters in clots imaged by SEM.
Using both AFM and SEM, we measured an increase in fiber diameter under all conditions of
ProliNONOate exposure (Figure 2). ProliNONOate added immediately following thrombin
addition significantly increased fiber diameter determined by AFM from the control diameter of
135 ± 34 nm to 161 ± 41 (p < 0.01). We also measured a significant increase in fiber diameter
when ProliNONOate was added to fibrinogen or thrombin independently. The addition of

ProliNONOate to thrombin increased the fiber diameter determined by AFM to 168 ± 43 (p <
0.01, compared to control) and the addition ProliNONOate to fibrinogen increased AFM
determined fiber diameter to 155 ± 37 (p < 0.01, compared to control).
We saw the same significant increases in fiber diameter when diameters were determined by
SEM. Differences in the average diameters reported by the two techniques hint toward the
independent limitations of the techniques. As mentioned above, the AFM requires contact
during measurements and that contact can affect height and width measurements and likewise,
sample dehydration needed for traditional SEM measurements can affect fiber diameters.
However, the significant change in diameter was consistent through both techniques. As
before, we saw a larger change in diameter when ProliNONOate was added to thrombin.
However, the addition of ProliNONOate to both proteins affected fiber diameters.

13

Fiber formation kinetics
The measured changes in clot fiber density and diameter suggest altered fibrin polymerization
kinetics. We measured the rate for fiber formation by UV-vis spectroscopy. The addition of NO
to thrombin before clot initiation significantly decreased the initial rate of clot formation from (2.4
± 0.6) x 10-3 OD/s to (1.3 ± 0.7) x 10-3 OD/s and increased the clotting time from 62 ± 20 s to

77 ± 30 s (p < 0.05, Figure 3, Table 1). The addition of NO to fibrin before clot formation

trended towards a longer clotting time and a decreased initial rate of formation however; the
results were not significant (p > 0.05, Table 1).

Fiber Extensibilty
Changes in protofibril lateral aggregation can affect clot density, fiber diameter and clot kinetics.
Therefore, our data above support altered protofibril lateral aggregation. The mechanism
behind alter protofibril lateral aggregation may be related to differences in molecular interaction
between protofibrils or due to the concentration of fibrin present in solution which can be altered
by thrombin activity, thrombin concentration of fibrinogen concentration.
Fiber extensibility measurements may give some insight into altered molecular interactions
between protofibrils. The mechanism of the extraordinary extensibility fibrin fibers is not
completely known. Initial extensibility is thought to be due to extension of the coiled-coil region
into beta sheets and unfolding of the globular gammaC domains [38,41,42]. However, the
lengthening due to these changes only account for a small portion of the fibers extensibility.
One hypothesis is that further extension comes from alphaC extension and protofibril sliding
[38,41,42]. Therefore, the strength of protofibril interactions may affect fiber extensibility.

To test this hypothesis, we measured the extensibility of fibrin fibers using an AFM (data not
shown). We saw no change in extensibility when NO was added to clots during or prior to clot
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initiation (p > 0.05). Fibers formed in the absence of NO had an extensibility of 182 % ± 36 %.

Fibers formed when NO was added to thrombin or fibrinogen prior to clot formation or when NO
was added immediately following the addition of thrombin to the fibrinogen solution had average
extensibilities ranging from 158 % ± 59 % to 201 % ± 35 %, none of which were significant

when compared to the control. The extensibility measurements agree with previously reported
values for crosslinked fibrin fibers [43].

Protein Modification
To help explain the measured changes in clot fiber density, diameter and kinetics with the
addition of ProliNONOate, we tested the samples for protein oxidation and S-nitrosation. We
repeated the protein modification assays in duplicate and report a weighted average. Under the
sample conditions we would not expect abundant formation protein S-nitrosation or oxidation
products. Protein S-nitrosation requires the formation of a nitrosonium ion, NO+, or
transnitrosation from low molecular weight nitrosothiols such as S-nitrosocysteine [44] and
oxidative products such as tyrosine nitration and carbonyl formation require superoxide and NO
to form the species peroxinitrite.

As expected when we used an ozone chemiluminescence system to measure protein Snitrosation, we detected low fibrinogen nitrosylation, 6 ± 3 mmole S-nitrosothiol per mole of
protein. Interestingly, α-thrombin contained 90 ± 40 mmole S-nitrosothiol per mole of protein.
Additionally, we used a competitive ELISA to measure protein tyrosine nitration and found 2 ± 2
mmole nitrated tyrosine per mole of fibrinogen and 160 ± 90 mmole nitrated tyrosine per mole of
thrombin. The quantitative value of the nitration assay must be considered with some caution
as the standard curve for tyrosine nitration used nitrated BSA and the affinity of the antibody for
nitrated thrombin or fibrinogen may vary. Lastly we measured carbonyl formation using an
alkaline DNPH assay. With the addition of 5 uM ProliNONOate carbonyl levels were below the
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detection limit of the assay, however increasing ProliNONOate 10-fold, to 50 uM produced 880
± 480 mmol of carbonyls per mole of fibrinogen and 390 ± 80 mmol of carbonyls per mole of
thrombin. This supports the assumption that carbonyls are produced through exposure of
proteins to ProliNONOate. A summary of the results of the protein modification assays are
shown in Table 2. Thrombin has a larger amount of protein modifications in the tyrosine nitration
and s-nitrosylation assays. We believe this is due to the higher ProliNONOate concentration (5
µM) to protein ratio for these thrombin samples (2 NIH u/ml or 18 nM) compared to the
corresponding fibrinogen samples (1 mg/ml or 2900 nM).

Discussion
The addition of NO donor ProliNONOate to the fibrin clot following the addition of thrombin led
to changes in the resulting fibrin clot. Fibrin clots formed in the presences of NO had a lower
fiber density, larger fiber diameters and had a slower rate of fiber formation. By testing the
effect of ProliNONOate on fibrinogen and thrombin independently we found that ProliNONOate
exposure altered clots through interaction with fibrinogen and/or thrombin.

Changes in structural properties, like those reported in our data, are often the result of altered
formation kinetics which are due to changes in intermolecular interactions, thrombin activity or
thrombin or fibrinogen concentration. In regards to enzymatic activity, a decrease in thrombin
activity is known to increase fibrin fiber diameter and decrease the fiber density of the clot
[9,45,46]. In the presence of NO, we measured a decrease in the rate of polymerization,
increase in fiber height by AFM and a decrease in fiber density of the clot, indicative of
decreased thrombin activity. We measured 39 % carbonyl formation and 9 % S-nitrosation of
thormbin. De Cristofaro et al reported a decrease in the catalytic efficiency of thrombin with

16
oxidation [47] and Lundbald et al showed a decrease of thrombin enzymatic activity with
oxidation [29].

Additionally, we saw changes when NO was added directly to fibrinogen prior to clot initiation.
The addition of NO to fibrinogen decreased clot density, increased fiber diameter and
decreased the rate of clot formation. The quantity of S-nitrosated and tyrosine nitrated
fibrinogen after NO exposure was low with 6 mmol of S-nitrosothiols per mole of protein;
however, we measured a carbonyl concentration of 100 mmol per mole of fibrinogen. These
data build on the changes in fibrin clot kinetics due to fibrinogen oxidation reported by Vadseth
et al [3].

Vadseth et al. reported a decrease in the initial rate of fiber formation with 1.5 carbonyls per
fibrinogen monomer [3]. This is consistent with our reported trend of a decrease in rate of clot
formation. However, Vadseth et al. also reported an increase in the rate of clot formation at very
low levels of tyrosine nitration, approximately 8 mmol of nitrotyrosines per mole of proteins [3]
and data by Parastatidis et al. measured an increase in the rate for fibrin formation, altered clot
structure, increased fibrin stiffness and a decrease in clot lysis in the presence of fibrinogen
nitration [2].

Similar fibrinogen tyrosine nitration levels in our samples to those of Vadseth did not lead to an
increase rate of clot formation. We believe this is due to a balance between fibrinogen tyrosine
nitration and fibrinogen carbonyls. The significant but smaller effect on fiber kinetics, diameter,
and fibrin clot density of fibrinogen exposure to ProliNONOate when compared to thrombin may
be due to the competing mechanisms of carbonyls and fibrinogen nitration.
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Our results suggest that exposure of fibrinogen and thrombin to ProliNONOate lead to the
measured clot changes through protein oxidation which decreased the activity of thrombin and
altered fibrin polymerization. However, the mechanism of oxidation upon NO exposure is
unclear. A common pathway of protein oxidation requires the formation of peroxynitrite form NO
and superoxide which should only exist in trace quantities in our solution. Therefore, we will
focus future work on identifying the mechanism of oxidation to ensure the changes in clot
structure are indeed due to oxidation and not another NO protein interaction.

NO is a small biological molecule produced by endothelial cells that line blood vessels. Its
bioavailability is an active research area and varies substantially under disease conditions.
Although the concentration of NO used in this study was high, elevated levels of tyrosine
nitration has been measured in vivo [2,3].

Our data show NO exposure altered fibrin clot density, fiber diameter, and fiber formation
kinetics. Measurement of protein oxidation suggest these changes are due to protein
modifications. Previous studies report oxidative modifications to fibrinogen both increase and
decrease the rate of fiber formation. He we show NO exposure leads to modifications that when
considered cumulatively decrease the rate of fiber formation and consequently lead to
associated structural changes.
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Figure Captions

Figure 1. Confocal images of (A) a control sample, (B) a sample with 5 µM ProliNONOate
added at clot initiation (NO + All), (C) a sample with 5 µM ProliNONOate add to thrombin prior to
clot initiation, (D) and a sample with 5 µM ProliNONOate add to fibrinogen prior to clot initiation.
All images were taken under the same magnification. E) Lines spaced at 10 µm intervals were
laid over the 238 x 238 µm images and the average number of fibers intersecting a line was
calculated to determine fiber density of the clots. The graph displays the fiber density of clots
formed under various conditions (average ± standard deviation, * p < 0.05, ** p < 0.01, n ranges

from 13 to 20 clots).

Figure 2. Atomic force microscopy (AFM) analysis of dried fibrin fiber formed with 1 mg/ml
fibrinogen, 0.5 NIH u/ml thrombin and 55 Lowey u/ml FXIII on top of cleaved mica. Samples
polymerize for two hours, after which they were rinsed with water and air dried. A) A height map
of an intermittent contact scan of a region of mica with dried fibers. B) Plot of height along the
line segment indicated in A. Fiber diameters were determined from such line segments. The
blue lines indicate the position at which the width at half the maximum height was determined.
C) Bar graph of the average diameter of dry fibers formed under various conditions and imaged
by AFM (error bars represent the standard deviation, * p < 0.001, n ≥ 40 fibers). D) Scanning
electron micrograph of a fibrin clot. We measured the diameters of fibers in the SEM images
using Image J. E) Bar graph of the average diameter of fibrin fibers formed under various
conditions and imaged by SEM (error bars represent the standard deviation, * p < 0.001, n ≥ 23 150
fibers).
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Figure 3. Spectrophotometer measurements of absorbance during fiber formation. Absorbance
measurements were taken every 10 seconds at 350 nm during fiber polymerization. A)
Absorbance versus time plots for control (black) and NO added to thrombin prior to clot
formation (gray). The shadowing surrounding the solid lines indicates the standard deviation of
the measurements. The control reaches its max OD around 3600 s and stops before the end
of the graph. The inset is an enlargement of the first two minutes of polymerization. B)
Absorbance versus time plots for control (black) and NO added to fibrinogen prior to clot
formation (gray). The shadowing surrounding the solid lines indicates the standard deviation of the
measurements. For reference, NO added to thrombin prior to clot formation is indicated by a
dashed black line.
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Table 1 Turbidity measurements
Initial rate
(OD/s)

Rate at ½ max OD
(OD/s)

Clotting time
(s)

Control

0.0024 ± 0.0007

0.0015 ± 0.0012

62 ± 20

Thrombin + NO

0.0013 ± 0.0009†

0.0004 ± 0.0001†

77 ± 30

Fibrinogen + NO

0.0017 ± 0.0010

0.0008 ± 0.0004

80 ± 35

†p

< 0.05 when compared to control

Table 2 Protein modification
Fibrinogen
(mmol/mole protein)

Thrombin
(mmol/mole protein)

S-nitrosation

6 ±3

90 ± 40

Tyrosine Nitration

2 ±2

160 ± 90

880 ± 480*

390 ± 80*

Carbonyl

Data is the weighted average and weighted standard deviation
*50 µM ProliNONOate was used in this assay, 10-fold higher than the other assays. Data is the average
and standard deviation

